These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20820138)

  • 1. [Therapeutic effect of omalizumab on 10 patients with severe persistent asthma].
    Kanemitsu Y; Kita H; Fuseya Y; Tanimura K; Katayama Y; Nisihara Y
    Arerugi; 2010 Aug; 59(8):965-73. PubMed ID: 20820138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
    Humbert M; Berger W; Rapatz G; Turk F
    Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in quality of life with omalizumab in patients with severe allergic asthma.
    Chipps B; Buhl R; Beeh KM; Fox H; Thomas K; Reisner C
    Curr Med Res Opin; 2006 Nov; 22(11):2201-8. PubMed ID: 17076981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
    Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
    J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
    Ohta K; Yamamoto M; Sato N; Ikeda K; Miyamoto T
    Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy with omalizumab in patients with severe persistent allergic asthma: a real life data in Turkey].
    Bavbek S; Aydın O; Kepil Özdemir S; Yılmaz I; Celik GE; Demirel YS; Mungan D; Sin B; Kurşun N; Mısırlıgil Z
    Tuberk Toraks; 2010; 58(4):425-34. PubMed ID: 21341120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
    Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens].
    Sugino Y; Sanda R; Takagi Y; Kato M; Ohta A; Okumura J; Nagai H
    Arerugi; 2010 Nov; 59(11):1572-9. PubMed ID: 21119303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the Asthma Control Composite outcome measure to predict omalizumab response.
    Harris JM; Wong DA; Kapp AV
    Ann Allergy Asthma Immunol; 2011 Sep; 107(3):273-80.e1. PubMed ID: 21875548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.